AN2 Therapeutics, Inc. (ANTX)
After hours:
Chart Events
Performance Outlook
| Previous Close | 8.78 |
| Open | 8.65 |
| Bid | 8.58 x 800 |
| Ask | 8.75 x 900 |
| Day's Range | 8.41 - 9.85 |
| 52 Week Range | 7.43 - 23.58 |
| Volume | |
| Avg. Volume | 81,041 |
| Market Cap | N/A |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 24.67 |
- GlobeNewswire
AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
On Track for Several Milestones in 2022, and Supported by Strong Balance Sheet from Upsized Initial Public Offering Continued Progress Advancing Epetraborole Clinical Program with Enrollment for Pivotal Phase 2/3 Trial in Treatment-Refractory MAC Lung Disease Expected to Begin in First Half of 2022 AN2 Board Strengthened through Appointment of Key Industry Executives MENLO PARK, Calif., May 10, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical com
- Business Wire
AN2 Therapeutics Appoints Maggie FitzPatrick to Its Board of Directors
MENLO PARK, Calif., May 09, 2022--AN2 Therapeutics, Inc., (NASDAQ: ANTX) a clinical-stage biopharmaceutical company developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today announced the appointment of Maggie FitzPatrick to its Board of Directors.
- American City Business Journals
Here are the Bay Area's biggest startup exits of the first quarter
The collective valuation of the 10 biggest first quarter exits of 2022 among local companies was less than a tenth of that of the top 10 from the same period last year.
